230 related articles for article (PubMed ID: 24993051)
1. 4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany.
Eichner M; Schwehm M; Hain J; Uphoff H; Salzberger B; Knuf M; Schmidt-Ott R
BMC Infect Dis; 2014 Jul; 14():365. PubMed ID: 24993051
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
Kieninger D; Sheldon E; Lin WY; Yu CJ; Bayas JM; Gabor JJ; Esen M; Fernandez Roure JL; Narejos Perez S; Alvarez Sanchez C; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
BMC Infect Dis; 2013 Jul; 13():343. PubMed ID: 23883186
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.
Domachowske JB; Pankow-Culot H; Bautista M; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
J Infect Dis; 2013 Jun; 207(12):1878-87. PubMed ID: 23470848
[TBL] [Abstract][Full Text] [Related]
4. Simulation studies to assess the long-term effects of Japan's change from trivalent to quadrivalent influenza vaccination.
Tsuzuki S; Schwehm M; Eichner M
Vaccine; 2018 Jan; 36(5):624-630. PubMed ID: 29292176
[TBL] [Abstract][Full Text] [Related]
5. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine.
Reed C; Meltzer MI; Finelli L; Fiore A
Vaccine; 2012 Mar; 30(11):1993-8. PubMed ID: 22226861
[TBL] [Abstract][Full Text] [Related]
6. Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia.
Jamotte A; Chong CF; Manton A; Macabeo B; Toumi M
BMC Public Health; 2016 Jul; 16():630. PubMed ID: 27449665
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults.
Song JY; Lee J; Woo HJ; Wie SH; Lee JS; Kim SW; Kim TH; Jung SI; Noh JY; Choi WS; Cheong HJ; Kim WJ
Hum Vaccin Immunother; 2019; 15(3):710-716. PubMed ID: 30396317
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age.
Greenberg DP; Robertson CA; Landolfi VA; Bhaumik A; Senders SD; Decker MD
Pediatr Infect Dis J; 2014 Jun; 33(6):630-6. PubMed ID: 24445833
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.
Beran J; Peeters M; Dewé W; Raupachová J; Hobzová L; Devaster JM
BMC Infect Dis; 2013 May; 13():224. PubMed ID: 23688546
[TBL] [Abstract][Full Text] [Related]
12. Retrospective public health impact of a quadrivalent influenza vaccine in the United States.
Crépey P; de Boer PT; Postma MJ; Pitman R
Influenza Other Respir Viruses; 2015 Aug; 9 Suppl 1(Suppl 1):39-46. PubMed ID: 26256294
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
Tinoco JC; Pavia-Ruz N; Cruz-Valdez A; Aranza Doniz C; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
Vaccine; 2014 Mar; 32(13):1480-7. PubMed ID: 24486352
[TBL] [Abstract][Full Text] [Related]
14. Quadrivalent versus trivalent influenza vaccine: clinical outcomes in two influenza seasons, historical cohort study.
Shasha D; Valinsky L; Hershkowitz Sikron F; Glatman-Freedman A; Mandelboim M; Toledano A; Paran Y; Ben-Ami R; Goldman D
Clin Microbiol Infect; 2020 Jan; 26(1):101-106. PubMed ID: 31108229
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials.
Moa AM; Chughtai AA; Muscatello DJ; Turner RM; MacIntyre CR
Vaccine; 2016 Jul; 34(35):4092-4102. PubMed ID: 27381642
[TBL] [Abstract][Full Text] [Related]
16. Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.
Dolk C; Eichner M; Welte R; Anastassopoulou A; Van Bellinghen LA; Poulsen Nautrup B; Van Vlaenderen I; Schmidt-Ott R; Schwehm M; Postma M
Pharmacoeconomics; 2016 Dec; 34(12):1299-1308. PubMed ID: 27647004
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
Yang MC; Tan EC; Su JJ
Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents.
Huang C; Fu X; Zhou Y; Mi F; Tian G; Liu X; Wu J; Ding C; Yan D; Li L; Yang S
Vaccine; 2020 Feb; 38(6):1332-1344. PubMed ID: 31948819
[TBL] [Abstract][Full Text] [Related]
19. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
van de Witte S; Nauta J; Montomoli E; Weckx J
Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
[TBL] [Abstract][Full Text] [Related]
20. Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model.
Rudenko L; Kiseleva I; Krutikova E; Stepanova E; Rekstin A; Donina S; Pisareva M; Grigorieva E; Kryshen K; Muzhikyan A; Makarova M; Sparrow EG; Torelli G; Kieny MP
PLoS One; 2018; 13(12):e0208028. PubMed ID: 30507951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
